Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin in combination with ifosfamide and etoposide (ICE) for reimbursement as a treatment option for the treatment of relapsed/refractory Non Hodgkin's Lymphoma. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.
This is written in the approval document as:
Treatment of relapsed / refractory Non Hodgkin's Lymphoma. Rituximab to be included in CD20 positive patients.
Citation
(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/397.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Carboplatin, Etoposide, Ifosfamide, Rituximab |